| __timestamp | CRISPR Therapeutics AG | Evotec SE |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 17990000 |
| Thursday, January 1, 2015 | 13403000 | 25166000 |
| Friday, January 1, 2016 | 31056000 | 27013000 |
| Sunday, January 1, 2017 | 35845000 | 42383000 |
| Monday, January 1, 2018 | 48294000 | 57012000 |
| Tuesday, January 1, 2019 | 63488000 | 66546000 |
| Wednesday, January 1, 2020 | 88208000 | 77238000 |
| Friday, January 1, 2021 | 102802000 | 105445000 |
| Saturday, January 1, 2022 | 102464000 | 156190000 |
| Sunday, January 1, 2023 | 76162000 | 169610000 |
| Monday, January 1, 2024 | 72977000 |
Cracking the code
In the dynamic world of biotechnology, understanding the financial health of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: CRISPR Therapeutics AG and Evotec SE, from 2014 to 2023. Over this period, Evotec SE consistently outpaced CRISPR Therapeutics AG in SG&A spending, peaking in 2023 with expenses nearly 123% higher than in 2014. Meanwhile, CRISPR Therapeutics AG saw a significant rise, with a 1,390% increase from 2014 to its peak in 2021. This trend reflects strategic investments in research and development, marketing, and administrative functions, essential for sustaining growth and innovation. As the biotech industry continues to evolve, monitoring these financial metrics provides valuable insights into the operational strategies and market positioning of these companies.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs CRISPR Therapeutics AG Trends and Insights
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Evotec SE
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Catalent, Inc. and Evotec SE
Breaking Down SG&A Expenses: Lantheus Holdings, Inc. vs Evotec SE
SG&A Efficiency Analysis: Comparing CRISPR Therapeutics AG and Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Perrigo Company plc
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Evotec SE
Protagonist Therapeutics, Inc. vs Evotec SE: SG&A Expense Trends